Distinguished in Large-Cell Lung Carcinoma

Dr. Matthew A. Gubens

Oncology
University Of California San Francisco
1600 Divisadero St, Mcb302, 
San Francisco, CA 
Offers Telehealth
Distinguished in Large-Cell Lung Carcinoma
University Of California San Francisco
1600 Divisadero St, Mcb302, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Gubens is an Oncologist in San Francisco, California. Dr. Gubens is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thymic Epithelial Tumor, and Lung Adenocarcinoma.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
1600 Divisadero St, Mcb302, San Francisco, CA 94115
Other Locations
REGENTS OF THE UNIVERSITY OF CALIFORNIA
400 Parnassus Ave, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: March 04, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium
Study Phase: Phase 2
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: October 13, 2021
Intervention Type: Biological
Study Drugs: TG4010, Nivolumab
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Enrollment Status: Completed
Publish Date: January 12, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

72 Total Publications

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 10, 2025
Similar Doctors
Distinguished in Large-Cell Lung Carcinoma
Dr. Joel W. Neal
Oncology | Hematology Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Joel W. Neal
Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Neal is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Neal is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Distinguished in Large-Cell Lung Carcinoma
Dr. Heather A. Wakelee
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Heather A. Wakelee
Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Heather Wakelee is an Oncologist in Stanford, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.

Distinguished in Large-Cell Lung Carcinoma
Dr. Kavitha J. Ramchandran
Oncology | Palliative Medicine | Hematology Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Kavitha J. Ramchandran
Oncology | Palliative Medicine | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kavitha Ramchandran is an Oncologist and a Palliative Medicine provider in Stanford, California. Dr. Ramchandran is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gubens's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile